Kmpharmaceutical케이엠제약
225430 · KOSDAQ · ₩225430 · 케이엠제약
₩698 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 22.3% | 24.0% | 24.9% | 27.6% | 20.6% | 24.9% |
| Operating margin | −17.1% | −18.3% | −17.7% | −6.1% | −8.0% | 3.8% |
| Net margin | −22.2% | −24.8% | −31.6% | −7.4% | −25.1% | −2.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +6.2% | +10.5% | −18.5% | +13.7% | −31.2% | — |
| Operating income growth | +0.6% | −13.8% | −135.6% | +12.5% | −243.9% | — |
| Net income growth | +5.2% | +13.2% | −246.5% | +66.4% | −542.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −13.7% | −13.0% | −13.4% | −3.7% | −10.3% | −1.5% |
| Return on assets | −8.0% | −8.3% | −9.2% | −2.6% | −7.6% | −1.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 78.9% | 64.1% | 50.2% | 42.5% | 41.2% | 32.0% |
| Net debt to equity | 43.2% | 37.6% | 42.7% | 32.1% | 35.0% | 18.6% |
| Current ratio | 27.6% | 31.7% | 50.6% | 50.3% | 50.8% | 131.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kmpharmaceutical / 케이엠제약 / 225430 / KRX:225430
Source: KRX statistical information